JP2023549872A5 - - Google Patents
Info
- Publication number
- JP2023549872A5 JP2023549872A5 JP2023529055A JP2023529055A JP2023549872A5 JP 2023549872 A5 JP2023549872 A5 JP 2023549872A5 JP 2023529055 A JP2023529055 A JP 2023529055A JP 2023529055 A JP2023529055 A JP 2023529055A JP 2023549872 A5 JP2023549872 A5 JP 2023549872A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- composition according
- section
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115286P | 2020-11-18 | 2020-11-18 | |
| US63/115,286 | 2020-11-18 | ||
| PCT/EP2021/081971 WO2022106460A2 (en) | 2020-11-18 | 2021-11-17 | Steroid sparing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549872A JP2023549872A (ja) | 2023-11-29 |
| JP2023549872A5 true JP2023549872A5 (enExample) | 2024-07-29 |
Family
ID=78819991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023529055A Pending JP2023549872A (ja) | 2020-11-18 | 2021-11-17 | ステロイド節約 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240327529A1 (enExample) |
| EP (1) | EP4247423A2 (enExample) |
| JP (1) | JP2023549872A (enExample) |
| KR (1) | KR20230110304A (enExample) |
| CN (1) | CN116997359A (enExample) |
| AU (1) | AU2021383537A1 (enExample) |
| CA (1) | CA3200884A1 (enExample) |
| IL (1) | IL302871A (enExample) |
| TW (1) | TW202241945A (enExample) |
| WO (1) | WO2022106460A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120392997A (zh) * | 2021-04-23 | 2025-08-01 | 阿斯利康(瑞典)有限公司 | 用于皮下注射的抗ifnar1给药方案 |
| WO2024100139A1 (en) * | 2022-11-09 | 2024-05-16 | Merck Patent Gmbh | Use of ifn-i activity as a biomarker for tlr inhibitor treatment |
| WO2025022280A1 (en) * | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| AR046833A1 (es) | 2003-11-10 | 2005-12-28 | Schering Corp | Anticuerpos anti-interleuquina-10 |
| KR101225299B1 (ko) | 2003-12-10 | 2013-01-24 | 메다렉스, 인코포레이티드 | 인터페론 알파 항체 및 그의 용도 |
| US7662381B2 (en) | 2004-06-21 | 2010-02-16 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
| KR20160070165A (ko) | 2008-02-08 | 2016-06-17 | 메디뮨 엘엘씨 | Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체 |
| CA2772921A1 (en) | 2009-09-03 | 2011-03-10 | Medimmune, Llc | Type 1 interferon diagnostic |
| JP2013511994A (ja) | 2009-11-30 | 2013-04-11 | バイオテスト・アクチエンゲゼルシヤフト | 全身性エリテマトーデス（ｓｌｅ）を治療するためのヒト化抗ｉｌ−１０抗体 |
| US20110281374A1 (en) * | 2010-05-12 | 2011-11-17 | Rainger George Edward | Biomarker |
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| CN106243226B (zh) | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| US20210349088A1 (en) * | 2018-10-18 | 2021-11-11 | Oklahoma Medical Research Foundation | Biomarkers For A Systemic Lupus Erythematosus (SLE) Disease Activity Immune Index That Characterizes Disease Activity |
| EP4494712A3 (en) * | 2019-11-11 | 2025-03-26 | Astrazeneca AB | Type i interferon inhibition in systemic lupus erythematosus |
| EP4157873A2 (en) * | 2020-05-29 | 2023-04-05 | Astrazeneca AB | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling |
| CN120392997A (zh) * | 2021-04-23 | 2025-08-01 | 阿斯利康(瑞典)有限公司 | 用于皮下注射的抗ifnar1给药方案 |
-
2021
- 2021-11-17 WO PCT/EP2021/081971 patent/WO2022106460A2/en not_active Ceased
- 2021-11-17 CN CN202180077088.5A patent/CN116997359A/zh active Pending
- 2021-11-17 JP JP2023529055A patent/JP2023549872A/ja active Pending
- 2021-11-17 IL IL302871A patent/IL302871A/en unknown
- 2021-11-17 KR KR1020237020189A patent/KR20230110304A/ko active Pending
- 2021-11-17 US US18/253,280 patent/US20240327529A1/en active Pending
- 2021-11-17 EP EP21816350.9A patent/EP4247423A2/en active Pending
- 2021-11-17 AU AU2021383537A patent/AU2021383537A1/en active Pending
- 2021-11-17 CA CA3200884A patent/CA3200884A1/en active Pending
- 2021-11-18 TW TW110142865A patent/TW202241945A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023002562A (ja) | 抗ｔｌ１ａモノクローナル抗体の中和 | |
| EP4114465B1 (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| JP2026048776A (ja) | 炎症性疾患の処置法 | |
| JP2023549872A5 (enExample) | ||
| CN113876947A (zh) | Il-17抗体的药物产品和稳定液体组合物 | |
| JP2011526244A (ja) | 炎症の処置方法 | |
| AU2003220439A1 (en) | Methods for treating chronic obstructive pulmonary disease (copd) | |
| JP2021152021A (ja) | 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用 | |
| TW202019477A (zh) | BCMAxCD3抗體構建體之給藥方案 | |
| KR20120105429A (ko) | 염증 치료 방법 | |
| KR20210100638A (ko) | 호중구 질환을 치료하는 방법 | |
| WO2019084307A1 (en) | ANTI-MERTK ANTIBODIES AND METHODS OF USE | |
| KR20190141148A (ko) | 소아 장애를 치료하는 방법 | |
| CN115551886A (zh) | 用于ttr淀粉样变性的联合疗法 | |
| CN112105387A (zh) | 特应性皮炎的治疗 | |
| JP2019536756A (ja) | Ｉｌ−２３ａ抗体を用いて疾患を処置する方法 | |
| US20240327529A1 (en) | Steroid sparing | |
| CN115667309A (zh) | 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病 | |
| JP7722989B2 (ja) | がんを治療するための方法及び組成物 | |
| CN119486744A (zh) | 艾萨妥昔单抗联合其他药物用于治疗多发性骨髓瘤的用途 | |
| JP2022104920A (ja) | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン | |
| AU2018263159A1 (en) | Methods of selectively treating asthma using IL-17 antagonists | |
| JP2024522095A5 (enExample) | ||
| JP2023550311A (ja) | 多発性骨髄腫の処置のための、イサツキシマブの使用 | |
| KR20210060582A (ko) | 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체 |